A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Inclusion Criteria:

1. Willingness to provide written informed consent and follow the study treatment planand visit plan;

2. Aged ≥ 18 years at time of signing informed consent, male or female;

3. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1;

4. Have life expectancy of at least 12 weeks ;

5. Subject with at least one measurable tumor lesion,according to the evaluationstandard of solid tumor efficacy (RECIST 1.1).

Exclusion criteria:

1. Subjects are allergic to LBL-007, PD-1 and similar compounds or any component in theprescription;

2. Subjects with active central nervous system metastases (regardless of whether theyhave received treatment), including symptomatic brain metastases, meningealmetastases, or spinal cord compression, but asymptomatic brain metastases (noprogression and/or at least 4 weeks after radiotherapy) No neurological symptoms orsigns after surgical resection, and dexamethasone or mannitol treatment is notrequired);

3. Have received major surgery within 4 weeks before the first administration;

4. Subjects can not tolerate intravenous administration and have difficulty in venousblood collection (if there is a history of fainting needles and bleeding);

5. Women during pregnancy or lactation;